Source comparison
PT-141 (Bremelanotide) vs PDE5 Inhibitors: Research Comparison
Mechanism of Action Melanocortin receptor agonist (MC4-R); central nervous system activation of sexual desire pathways PDE5 inhibitor; increases cGMP to enhance blood flow to genital tissue PDE5 inhibitor; longer half-life than sildenafil, same mechanism PT-14
This comparison does not assign a generated winner or score.
- Mechanism of Action
- Melanocortin receptor agonist (MC4-R); central nervous system activation of sexual desire pathways
- PDE5 inhibitor; increases cGMP to enhance blood flow to genital tissue
- PDE5 inhibitor; longer half-life than sildenafil, same mechanism
- PT-141 addresses desire; PDE5 inhibitors address mechanics
- Primary Indication
- Hypoactive sexual desire disorder (HSDD) in premenopausal women
- Erectile dysfunction in men
- Erectile dysfunction in men; also approved for BPH
- PT-141 fills a gap where vascular interventions don't apply
- Administration Route
- Subcutaneous injection (1.75mg as-needed, 45 min before activity)
- Oral tablet (25–100mg, 30–60 min before activity)
- Oral tablet (2.5–20mg daily or as-needed)
- Injection route limits PT-141's real-world adherence
- Onset of Action
- 30–45 minutes (desire) + 60–90 minutes (physiological arousal)
- 30–60 minutes
- 30 minutes (effect lasts 24–36 hours)
- PT-141's delayed onset complicates spontaneous-use scenarios
- Side Effect Profile
- Nausea (40%), facial flushing (20%), injection site reactions (15%)
- Headache (16%), flushing (10%), dyspepsia (7%)
- Headache (11%), back pain (6%), dyspepsia (5%)
- PT-141's nausea is dose-limiting; PDE5 side effects rarely cause discontinuation
- FDA Approval Status (2026)
- Approved 2019 for female HSDD; not approved for male dysfunction
- Approved 1998 for male ED
- Approved 2003 for male ED
- PT-141's approval is narrower due to side effect burden